Asia-Pacific Antimicrobial Susceptibility Testing Market - Indsutry Trends and Forecast to 2028

TABLE OF CONTENT

TABLE OF CONTENTS
1 INTRODUCTION 65
1.1 OBJECTIVES OF THE STUDY 65
1.2 MARKET DEFINITION 65
1.3 OVERVIEW OF ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 65
1.4 LIMITATIONS 67
1.5 MARKETS COVERED 67
2 MARKET SEGMENTATION 70
2.1 MARKETS COVERED 70
2.2 GEOGRAPHICAL SCOPE 71
2.3 YEARS CONSIDERED FOR THE STUDY 72
2.4 CURRENCY AND PRICING 72
2.5 DBMR TRIPOD DATA VALIDATION MODEL 73
2.6 MULTIVARIATE MODELLING 76
2.7 PRODUCT TYPE LIFELINE CURVE 77
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 78
2.9 DBMR MARKET POSITION GRID 79
2.10 MARKET APPLICATION COVERAGE GRID 80
2.11 VENDOR SHARE ANALYSIS 81
2.12 SECONDARY SOURCES 82
2.13 ASSUMPTIONS 82
3 EXECUTIVE SUMMARY 83
4 PREMIUM INSIGHTS 85
5 MARKET OVERVIEW 86
5.1 DRIVERS 88
5.1.1 RISING EPIDEMIC AND PANDEMIC OUTBREAK 88
5.1.2 GROWING HEALTHCARE EXPENDITURE 88
5.1.3 INCREASING ASIA PACIFIC PREVALENCE OF INFECTIOUS DISEASES 89
5.1.4 INCREASING PREVALENCE OF MULTI-DRUG RESISTANCE ORGANISM 89
5.1.5 GROWING INFRASTRUCTURE FACILITIES 89
5.1.6 HIGHER ADOPTION OF TECHNOLOGICALLY ADVANCED SUSCEPTIBILITY TESTING METHODS 90
5.2 RESTRAINTS 90
5.2.1 STRINGENT GOVERNMENT REGULATIONS 90
5.2.2 HIGH COSTS 91
5.2.3 SHORTAGE OF SKILLED PERSONNEL 91
5.3 OPPORTUNITIES 92
5.3.1 TECHNOLOGICAL ADVANCEMENTS 92
5.3.2 INVESTMENTS IN HEALTHCARE INFRASTRUCTURE 92
5.3.3 INFRASTRUCTURE OF NEW GENOMIC IDENTIFICATION METHODS 93
5.3.4 INCREASE IN FUNDING 93
5.4 CHALLENGES 94
5.4.1 EMERGENCE OF LOCAL PLAYER IN THE MARKETS 94
5.4.2 LACK OF CLINICAL DATA FROM FDA 94
5.4.3 DELAYS BETWEEN CLINICAL BREAKPOINT AND ITS CLEARANCE 94
6 IMPACT OF COVID-19 ON ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET 95
6.1 IMPACT ON PRICE 95
6.2 IMPACT ON DEMAND 95
6.3 IMPACT ON SUPPLY 95
6.4 KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19 96
6.5 CONCLUSION: 96
7 ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY PRODUCT TYPE 97
7.1 OVERVIEW 98
7.2 INSTRUMENTS 101
7.2.1 MANUAL 102
7.2.1.1 MINIATURIZED IDENTIFICATION SYSTEMS 102
7.2.1.2 SUSCEPTIBILITY TESTING DISCS 102
7.2.1.2.1 HEXA DISCS 103
7.2.1.2.1.1 GRAM NEGATIVE ORGANISM 103
7.2.1.2.1.2 GRAM POSITIVE ORGANISM 104
7.2.1.2.1.3 GENERAL PURPOSE 104
7.2.1.2.1.4 ANAEROBIC BACTERIA 104
7.2.1.2.1.5 ANTIFUNGAL 104
7.2.1.2.1.6 OTHERS 104
7.2.1.2.2 OCTA DISCS 104
7.2.1.2.2.1 GRAM NEGATIVE ORGANISM 105
7.2.1.2.2.2 GRAM POSITIVE ORGANISM 105
7.2.1.2.2.3 UTI ORGANISMS 105
7.2.1.2.2.4 PSEUDOMONAS 105
7.2.1.2.2.5 GENERAL PURPOSE 105

7.2.1.2.3 DODECA DISCS 106
7.2.1.2.3.1 GENERAL PURPOSE 106
7.2.1.2.3.2 GRAM NEGATIVE ORGANISM 106
7.2.1.2.3.3 GRAM POSITIVE ORGANISM 106
7.2.1.2.3.4 PSEUDOMONAS 106
7.2.1.2.3.5 UTI ORGANISMS 107
7.2.1.2.4 ICOSA DISCS 107
7.2.1.2.4.1 GENERAL PURPOSE 107
7.2.1.2.4.2 PSEUDOMONAS 107
7.2.1.2.4.3 UTI ORGANISMS 107
7.2.1.3 MIC STRIPS 107
7.2.1.3.1 COMBINATION ANTIBACTERIAL 108
7.2.1.3.2 DUAL ANTIBACTERIAL 108
7.2.1.3.3 MULTIPLE ANTIBACTERIAL 108
7.2.1.3.4 SINGLE ANTIBACTERIAL 108
7.2.1.3.5 ANTIFUNGAL 108
7.2.2 AUTOMATED IDENTIFICATION AND SUSCEPTIBILITY TESTING SYSTEM 108
7.3 CONSUMABLES & ACCESSORIES 109
7.3.1 REAGENT AND BROTHS 110
7.3.2 MEDIA 110
7.3.3 SUSCEPTIBILITY PANELS 110
7.3.4 OTHERS 110
7.4 SERVICES & SOFTWARE 110
8 ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET,BY METHOD 112
8.1 OVERVIEW 113
8.2 DISK DIFFUSION 116
8.3 DILUTION 116
8.4 MASS SPECTROMETRY METHOD 117
8.5 E-TESTS 117
8.6 GENOTYPIC METHODS 118
8.7 OTHERS 119
9 ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY TYPE 120
9.1 OVERVIEW 121
9.2 ANTIBACTERIAL TESTING 124
9.3 ANTIFUNGAL TESTING 124
9.4 OTHERS 125

10 ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY APPLICATION 126
10.1 OVERVIEW 127
10.2 CLINICAL DIAGNOSTICS 130
10.3 DRUG DISCOVERY AND DEVELOPMENT 131
10.4 EPIDEMIOLOGY 131
10.5 OTHERS 132
11 ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY END USER 134
11.1 OVERVIEW 135
11.2 HOSPITALS 138
11.3 DIAGNOSTIC LABORATORIES 139
11.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 140
11.5 CONTRACT RESEARCH ORGANISATION 140
11.6 RESEARCH CENTRES & ACADEMIC INSTITUTES 142
11.7 OTHERS 142
12 ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET, BY DISTRIBUTION CHANNEL 145
12.1 OVERVIEW 146
12.2 DIRECT SALES 149
12.3 RETAIL SALES 150
12.4 THIRD PARTY DISTRIBUTOR 150
13 ASIA PACIFIC ANTIMICROBIAL SUCEPTIBILITY TESTING MARKET BY GEOGRAPHY 152
13.1 OVERVIEW 152
13.2 ASIA PACIFIC 156
13.2.1 CHINA 165
13.2.2 JAPAN 170
13.2.3 INDIA 175
13.2.4 SOUTH KOREA 180
13.2.5 AUSTRALIA 185
13.2.6 SINGAPORE 190
13.2.7 THAILAND 195
13.2.8 MALAYSIA 200
13.2.9 INDONESIA 205
13.2.10 PHILIPPINES 210
13.2.11 REST OF ASIA-PACIFIC 215
14 ASIA PACIFIC ANTIMICROBIAL SUSCEPTIBILITY TESTING MARKET: COMPANY LANDSCAPE 216
14.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 216
15 SWOT 217
16 COMPANY PROFILE 218
16.1 THERMO FISHER SCIENTIFIC INC. 218
16.1.1 COMPANY SNAPSHOT 218
16.1.2 REVENUE ANALYSIS 218
16.1.3 COMPANY SHARE ANALYSIS 219
16.1.4 PRODUCT PORTFOLIO 219
16.1.5 RECENT DEVELOPMENTS 220
16.2 BIOMRIEUX SA 221
16.2.1 COMPANY SNAPSHOT 221
16.2.2 REVENUE ANALYSIS 221
16.2.3 COMPANY SHARE ANALYSIS 222
16.2.4 PRODUCT PORTFOLIO 222
16.2.5 RECENT DEVELOPMENTS 222
16.3 DANAHER 224
16.3.1 COMPANY SNAPSHOT 224
16.3.2 REVENUE ANALYSIS 224
16.3.3 COMPANY SHARE ANALYSIS 225
16.3.4 PRODUCT PORTFOLIO 225
16.3.5 RECENT DEVELOPMENTS 226
16.4 MERCK KGAA 228
16.4.1 COMPANY SNAPSHOT 228
16.4.2 REVENUE ANALYSIS 228
16.4.3 COMPANY SHARE ANALYSIS 229
16.4.4 PRODUCT PORTFOLIO 229
16.4.5 RECENT DEVELOPMENTS 229
16.5 ACCELERATE DIAGNOSTICS, INC. 231
16.5.1 COMPANY SNAPSHOT 231
16.5.2 REVENUE ANALYSIS 231
16.5.3 PRODUCT PORTFOLIO 232
16.5.4 RECENT DEVELOPMENTS 232
16.6 ALIFAX S.R.L. 233
16.6.1 COMPANY SNAPSHOT 233
16.6.2 PRODUCT PORTFOLIO 233
16.6.3 RECENT DEVELOPMENTS 234
16.7 BACTERIOSCAN, INC. 235
16.7.1 COMPANY SNAPSHOT 235
16.7.2 PRODUCT PORTFOLIO 235
16.7.3 RECENT DEVELOPMENTS 235
16.8 BD 237
16.8.1 COMPANY SNAPSHOT 237
16.8.2 REVENUE ANALYSIS 237
16.8.3 PRODUCT PORTFOLIO 238
16.8.4 RECENT DEVELOPMENTS 238
16.9 BIO-RAD LABORATORIES, INC. 240
16.9.1 COMPANY SNAPSHOT 240
16.9.2 REVENUE ANALYSIS 240
16.9.3 PRODUCT PORTFOLIO 241
16.9.4 RECENT DEVELOPMENTS 241
16.10 CREATIVE DIAGNOSTICS 242
16.10.1 COMPANY SNAPSHOT 242
16.10.2 PRODUCT PORTFOLIO 242
16.10.3 RECENT DEVELOPMENTS 242
16.11 ERBA GROUP 244
16.11.1 COMPANY SNAPSHOT 244
16.11.2 PRODUCT PORTFOLIO 244
16.11.3 RECENT DEVELOPMENTS 244
16.12 GENEFLUIDICS, INC. 246
16.12.1 COMPANY SNAPSHOT 246
16.12.2 PRODUCT PORTFOLIO 246
16.12.3 RECENT DEVELOPMENTS 246
16.13 HIMEDIA LABORATORIES 248
16.13.1 COMPANY SNAPSHOT 248
16.13.2 PRODUCT PORTFOLIO 248
16.13.3 RECENT DEVELOPMENTS 248
16.14 LIOFILCHEM S.R.L. 250
16.14.1 COMPANY SNAPSHOT 250
16.14.2 PRODUCT PORTFOLIO 250
16.14.3 RECENT DEVELOPMENTS 250
16.15 MAST GROUP LTD. 252
16.15.1 COMPANY SNAPSHOT 252
16.15.2 PRODUCT PORTFOLIO 252
16.15.3 RECENT DEVELOPMENTS 252

16.16 MERLIN GESELLSCHAFT FUR MICROBIOLOGISCHE DIAGNOSTIKA MBH 254
16.16.1 COMPANY SNAPSHOT 254
16.16.2 PRODUCT PORTFOLIO 254
16.16.3 RECENT DEVELOPMENTS 254
16.17 NUMEDII, INC. 256
16.17.1 COMPANY SNAPSHOT 256
16.17.2 TECHNOLOGY PORTFOLIO 256
16.17.3 RECENT DEVELOPMENTS 256
16.18 ROSCO DIAGNOSTICA A/S 258
16.18.1 COMPANY SNAPSHOT 258
16.18.2 PRODUCT PORTFOLIO 258
16.18.3 RECENT DEVELOPMENT 258
16.19 SYNBIOSIS 259
16.19.1 COMPANY SNAPSHOT 259
16.19.2 PRODUCT PORTFOLIO 259
16.19.3 RECENT DEVELOPMENTS 259
16.20 ZHUHAI DL BIOTECH CO., LTD 261
16.20.1 COMPANY SNAPSHOT 261
16.20.2 PRODUCT PORTFOLIO 261
16.20.3 RECENT DEVELOPMENT 261
17 QUESTIONNAIRE 262
18 RELATED REPORTS 265